// App-Quantinova.ai

564 : Combination therapy of chemokine receptor inhibition plus PD-L1 blockade potentiates antitumor effects in a murine model of breast cancer

Researchers

Presenter

  • Heiyoun Jung

Principal Investigators

  • Linda Ertl

  • Karen Ebsworth

  • Christine Janson

  • Penglie Zhang

  • Punna Sreenivas

  • Thomas Schall

  • Israel Charo

Medical Centers

  • ChemoCentryx, Mountain View, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Lung Cancer

  • Breast cancer

  • Solid malignancies

Biomarkers

  • C-C Motif Chemokine Ligand 5

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved